

Influenza A virus H5N1 subtype Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Influenza A virus H5N1 subtype

https://marketpublishers.com/r/I14BEA9A872EN.html

Date: September 2018

Pages: 65

Price: US\$ 1,200.00 (Single User License)

ID: I14BEA9A872EN

Abstracts

Influenza A virus H5N1 subtype Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Influenza A virus H5N1 subtype Infection pipeline products.

DISEASE OVERVIEW

Influenza A virus H5N1 subtype infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as 'lockjaw' as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.



REPORT DESCRIPTION

The Influenza A virus H5N1 subtype Infection pipeline guide presents complete overview of drugs currently being developed for Influenza A virus H5N1 subtype Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Influenza A virus H5N1 subtype Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Influenza A virus H5N1 subtype Infection pipeline candidates is included.

Major companies participating in therapeutic development of Influenza A virus H5N1 subtype Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Influenza A virus H5N1 subtype Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Influenza A virus H5N1 subtype Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Influenza A virus H5N1 subtype Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE REPORT INCLUDES

Panorama of Influenza A virus H5N1 subtype Infection pipeline markets including statistics on therapeutic drugs and companies involved



Influenza A virus H5N1 subtype Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Influenza A virus H5N1 subtype Infection pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Influenza A virus H5N1 subtype Infection pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Influenza A virus H5N1 subtype Infection pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Influenza A virus H5N1 subtype Infection pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Influenza A virus H5N1 subtype Infection pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company



Contents

I. KEY FINDINGS

 Companies Investing in Influenza A virus H5N1 subtype Infection Pipeline include Number of Companies with Influenza A virus H5N1 subtype Infection projects in preclinical Development

Number of Companies with Influenza A virus H5N1 subtype Infection projects in Clinical Development

Influenza A virus H5N1 subtype Infection Pipeline Companies based in Americas Influenza A virus H5N1 subtype Infection Pipeline Companies based in Europe Influenza A virus H5N1 subtype Infection Pipeline Companies based in Asia Pacific Influenza A virus H5N1 subtype Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include

Influenza A virus H5N1 subtype Infection Pipeline Agents in Pre- clinical/Discovery stage of Development

Influenza A virus H5N1 subtype Infection Pipeline Agents in Clinical Development stage

Influenza A virus H5N1 subtype Infection Pipeline Therapeutic Compounds received special status

Mechanism of Action of most pipeline Drugs

Small molecules among the Influenza A virus H5N1 subtype Infection Pipeline agents

II. INSIGHTS INTO INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE

1. Disease Overview

Introduction to Influenza A virus H5N1 subtype Infection
Symptoms and Causes of Influenza A virus H5N1 subtype Infection
Treatment or Prevention Options for Influenza A virus H5N1 subtype Infection
Other Details

2. Phase wise Pipeline Compounds

Influenza A virus H5N1 subtype Infection Pipeline Pre- Clinical/Discovery stage Drugs Influenza A virus H5N1 subtype Infection Pipeline Phase 1 stage Drugs Influenza A virus H5N1 subtype Infection Pipeline Phase 2 stage Drugs Influenza A virus H5N1 subtype Infection Pipeline Phase 3 stage Drugs Influenza A virus H5N1 subtype Infection Pipeline Pre-Registration stage Drugs

- 3. Company wise Influenza A virus H5N1 subtype Infection Pipeline Compounds
- 4. Influenza A virus H5N1 subtype Infection Pipeline by Mechanism of Action



III. INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE COMPOUND DETAILS

Neuraminidase inhibitor for H5N1

avian influenza vaccine

Pandemic influenza H5 and H1B vaccine

NasoVAX

Influenza A virus H5N1 vaccine

APP-0205

APP-309

MD 2009

BVX-M001

Nasal influenza vaccines

peptide treatment for H5N1

Small Molecules for Influenza A Virus H5N1

CHO-S05

CC-42344

CV7302

DP-C005

PN-SIA

PN-SIA

sirtuin-targeted drugs for influenza virus

GammaFlu

siRNA antivirals

GREFLU/VIE

Ampligen

KPT-335

KIN 1148

Influ-nRNA

H5N1 virus-like particle vaccine

influenza (H5, H7, H9 and H10)VLP vaccine

AT-301

FLU-CIDE

GelVac vaccine

influenza H5N1 vaccine

influenza virus haemagglutinin glycoprotein inhibitors

Baloxavir Marboxil

MV-4



Pandemic H5N1 vaccine split-virion H5N1 vaccine

VX-787

HB36.6

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

- 2. Drug Overview
- 3. Mechanism of Action
- 4. Current Status
- 5. Clinical Trial Details

IV. INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE COMPANY BRIEFS

Abzyme Therapeutics LLC

Akshaya Bio Inc

AlphaVax

Altimmune Inc

Antigen Express Inc

Aphios Corp

Aphios Corp

AusBio Ltd

BiondVax Pharmaceuticals Ltd

CaPtivate Pharmaceuticals LLC

CEL-SCI Corp

Chicago Biosolutions Inc

CHO Pharma Inc

Cocrystal Pharma Inc

Curevac AG

Declion Pharmaceuticals Inc

Fides Pharma SPA

Fides Pharma SPA

Forge Life Science LLC



Gamma Vaccines Pty Ltd

General Research Laboratory

Greffex Inc

Hemispherx Biopharma Inc

Karyopharm Therapeutics Inc

Kineta Inc

Lakewood-Amedex Inc

Medicago Inc

Medigen Inc

Medigen Vaccine Biologics Corp

NanoViricides Inc

Ology Bioservices Inc

OPKO Health Inc

PeptiDream Inc

Shionogi & Co Ltd

TGV Laboratories Inc

Tria Bioscience Corp

Vaxine Pty Ltd

Vertex Pharmaceuticals

Virvio Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL INFLUENZA A VIRUS H5N1 SUBTYPE INFECTION PIPELINE MARKET

VI. APPENDIX

- 1. Publisher's Expertise
- 2. Research Methodology
- 3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability



I would like to order

Product name: Influenza A virus H5N1 subtype Infection Drug Pipeline Study, H2 2018- Analysis of

Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Influenza A

virus H5N1 subtype

Product link: https://marketpublishers.com/r/I14BEA9A872EN.html

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l14BEA9A872EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970